TDDS vs ОРД: How to Choose the Right Film-Based Delivery Format

Transdermal drug delivery systems (TDDS) and oral dissolving films (ОРД) are often mentioned in the same breath — both are film-based dosage forms, both can be manufactured on continuous wet-coating platforms, and both represent alternatives to conventional solid oral dosage forms. For companies evaluating either format, or considering both, understanding where they converge and where they fundamentally diverge is essential for making the right product development and equipment investment decisions.

Huanghai manufactures continuous wet-coating platforms that support both ОРД and трансдермальный пластырь production, including the MJ150 coating machine and MJF180 cutting and packaging system. The shared platform creates real efficiencies — but the products themselves serve different therapeutic purposes, face different regulatory requirements, and require different material architectures.

What ОРД and TDDS Share: A Common Process Logic

The manufacturing process is where the two formats are most similar — and where a shared platform creates genuine value.

Both ОРД and TDDS manufactured by wet-coating follow the same basic process sequence:

• Formulation: A drug-containing matrix is prepared as a fluid (solution, suspension, or gel)
• Coating: The fluid is applied onto a moving substrate at controlled thickness via a coating head
• Drying: The coated web passes through a temperature-controlled drying tunnel where water or solvent is removed
• Conversion: The dried web is laminated (TDDS) or left as-is (ОРД), then slit and cut into individual units

Both formats share: - Continuous web processing (not batch) - The need for precise coating weight control - Sensitivity to drying conditions (temperature, airflow, residence time) - API uniformity requirements across the web - GMP cleanroom environment for фармацевтический-grade production

Huanghai's MJ150 platform can support both ОРД and TDDS production. Core modules are shared — however, switching between ОРД and TDDS formats involves format-specific tooling changes and changeover operations that require Huanghai engineering support. In practice, most customers operate separate dedicated lines for ОРД and TDDS.

Where ОРД and TDDS Diverge: Delivery Route and Product Design Goals

Despite the manufacturing similarities, the two formats serve fundamentally different therapeutic purposes — and this drives differences in formulation strategy, material selection, regulatory pathway, and post-processing requirements.

Delivery Route and Absorption Barrier

Dimension	ОРД (Oral Dissolving Film)	TDDS (трансдермальный пластырь)
Delivery route	Oral — placed on tongue or buccal mucosa	Dermal — applied to skin surface
Primary absorption barrier	Oral mucosa / gastrointestinal tract	Stratum corneum (skin's outer layer)
Onset profile	Typically faster — dissolves in seconds to minutes	Slower onset — hours to reach therapeutic levels; sustained for hours to days
Duration of action	Single dose, short to medium duration	Extended — patches typically worn 24 hours to 7 days
First-pass metabolism	Can be bypassed if buccal/sublingual absorption occurs; otherwise subject to GI first-pass	Largely bypassed — systemic absorption via skin avoids hepatic first-pass
Target patient	Patients with dysphagia, pediatric, rapid onset needs	Patients requiring sustained systemic levels, chronic conditions, соответствие-sensitive use
Best fit for	APIs suitable for oral/mucosal delivery; patient convenience for таблетка replacement	APIs requiring sustained release; those poorly absorbed orally or with significant first-pass metabolism

Formulation and Material Architecture

ОРД formulations are designed to dissolve rapidly in the oral cavity, releasing the API for absorption through the mucosa or swallowing for GI absorption. The film matrix uses water-soluble polymers (e.g., HPMC, pullulan, PVA) with plasticizers and taste-masking agents. The primary design challenge is achieving rapid dissolution, palatability, and dose uniformity in a thin film format.

TDDS formulations must achieve controlled API permeation across the skin barrier over an extended period. This requires: - Backing liner: Impermeable layer preventing API loss from the outer surface - Drug-containing matrix or reservoir: Engineered for controlled API release rate - Adhesive layer: Maintains skin contact throughout the wear period - Release liner: Peeled off before application

The material complexity is substantially higher in TDDS. The adhesive system must maintain skin contact for 24 hours to 7 days without causing irritation. Permeation enhancers are often required. The backing and release liner materials are selected for their barrier properties and compatibility with the drug matrix.

Regulatory Pathway and QC Requirements

Both formats are regulated as фармацевтический drug products in most markets, but the specific requirements differ:

Regulatory Element	ОРД	TDDS
Key pharmacopoeial tests	Content uniformity, disintegration time, dissolution	Content uniformity, in vitro drug release (IVRT), adhesive performance
Bioequivalence стандарт	стандарт oral BE or buccal absorption studies	In vitro-in vivo correlation (IVIVC) often required; BE studies specific to transdermal products
Stability тестирование	ICH conditions; packaging must prevent moisture uptake	ICH conditions; long-term skin adhesion performance included
Special considerations	Taste masking, polymer dissolution rate	Skin irritation тестирование, adhesive peel strength, cold flow resistance

Post-Processing Differences

After drying, ОРД processing involves: - Slitting the web to individual film dimensions - Cutting into unit doses - Packaging in unit-dose pouches (foil/foil or foil/transparent)

TDDS processing is more complex: - A backing liner must be laminated onto the dried drug matrix layer - The resulting composite web (backing / drug matrix / release liner) is then die-cut into patch shapes - Patch shapes may be square, round, or custom geometry - Individual patches are inserted into pouch packaging

The MJF180 automatic cutting and packaging system is designed primarily for ОРД conversion. TDDS post-processing — particularly the backing liner lamination step and die-cutting — may require format-specific tooling or separate conversion equipment depending on the patch design.

Practical Decision Framework

Use the following criteria to determine which format better fits your project:

Choose ОРД when: - The API is suitable for oral or mucosal absorption - Rapid onset is desired or required - The target patient population has difficulty swallowing conventional таблетки - Product differentiation from таблетки/капсулы is a marketing objective - The regulatory pathway for oral drug products is better established for your API

Choose TDDS when: - The API requires sustained systemic delivery over hours to days - Oral bioavailability is limited by first-pass metabolism or GI instability - Patient соответствие is a concern (once-daily or multi-day dosing preferred) - The API has established pharmacokinetic advantages via the transdermal route - The therapeutic indication requires steady-state plasma levels rather than peak-and-trough profiles

Consider both formats when: - You are developing a pipeline of film-based dosage forms and want platform flexibility - Your API candidates span both oral and transdermal applications - You want to offer both formats to different customer segments or markets

Huanghai's MJ150 platform — with its dual ОРД/TDDS capability — is particularly relevant for companies building platform capacity rather than committing to a single format. The shared wet-coating and drying infrastructure reduces capital investment compared to acquiring separate dedicated lines.

Frequently Asked Questions

Q: Can the same coating machine produce both ОРД and transdermal patches? A: Yes — this is one of the practical advantages of Huanghai's continuous wet-coating platform. The core coating and drying modules are compatible with both ОРД and TDDS production. The primary differences are in post-coating processing: ОРД requires simple slitting and cutting, while TDDS requires additional lamination of a backing liner and typically more complex die-cutting. Switching between formats on the MJ150 involves format-specific tooling changes that require Huanghai engineering support; in practice, most customers operate separate dedicated lines for each format. If dual-format capability on a single platform is a priority for your project, contact Huanghai to evaluate the configuration for your specific product requirements.

Q: Is ОРД or TDDS more established in terms of regulatory approval pathways? A: Both are well-established in major фармацевтический markets. ОРД has a longer commercial track record as a dosage form replacement for таблетки in pediatric and dysphagia applications. TDDS has equally well-established regulatory frameworks, particularly for pain management, smoking cessation, and hormone replacement — categories with numerous approved reference products. For new APIs, the choice of format depends on the pharmacokinetic profile of the drug rather than regulatory familiarity.

Q: Which format requires more complex formulation development? A: TDDS generally requires more complex formulation development than ОРД. The primary challenge in ОРД is achieving rapid dissolution and taste masking within a thin film. TDDS must additionally address skin permeation (a more difficult barrier than oral mucosa for most drugs), adhesive performance over the wear period, skin compatibility, and potentially permeation enhancement strategies. However, this complexity also means TDDS formulations tend to have higher barriers to competitive replication.

Q: What is the pilot-scale investment difference between ОРД and TDDS? A: At the pilot scale, equipment requirements are similar. Huanghai's MJ150-L lab-scale coating machine at 8,000–10,000 films/hour supports both ОРД and TDDS pilot production with the same process logic as the commercial platform. The incremental cost difference at pilot scale is primarily in post-coating tooling and materials (backing liner, die-cutting tools for TDDS vs. simpler slit-and-cut tooling for ОРД). Commercial-scale investment considerations should be discussed based on specific project parameters.

Conclusion

TDDS and ОРД share a manufacturing platform but serve distinctly different therapeutic purposes. The choice between them is primarily a product strategy decision — driven by the pharmacokinetics of your API, the clinical needs of your target patient population, and your regulatory pathway — not primarily an equipment decision.

For companies with the strategic flexibility to consider both formats, Huanghai's continuous wet-coating platform offers a practical path to building capacity that spans both product categories without requiring redundant capital investment.

Contact Huanghai to discuss your API profile, product strategy, and equipment configuration options for ОРД, TDDS, or both.

Looking to build your own TDDS manufacturing line? Explore our Complete TDDS Manufacturing Solution — covering precision coating equipment, adhesive mixing systems, and die-cutting for transdermal patches.

---

Полный перечень сертификатов и стандартов соответствия нашего оборудования доступен на странице Сертификаты и соответствие.